Cobimetinib

Overview

Cobimetinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL2146883).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Cobimetinib expires 30 Dec 2036 and exclusivity 28 Oct 2029. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone

Canonical SMILES

C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O

InChIKey

BSMCAPRUBJMWDF-KRWDZBQOSA-N